X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) released its earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, Zacks reports. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.
X4 Pharmaceuticals Stock Performance
NASDAQ XFOR traded up $0.07 during trading hours on Wednesday, reaching $3.24. The company’s stock had a trading volume of 536,564 shares, compared to its average volume of 641,872. The company has a current ratio of 11.30, a quick ratio of 11.02 and a debt-to-equity ratio of 0.49. The business has a 50-day simple moving average of $3.30 and a 200 day simple moving average of $3.79. X4 Pharmaceuticals has a 52 week low of $2.43 and a 52 week high of $4.83. The stock has a market cap of $321.25 million, a PE ratio of -2.70 and a beta of 0.47.
Insider Activity
In related news, Chairman Adam R. Craig sold 47,436 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the transaction, the chairman owned 328,651 shares in the company, valued at $1,459,210.44. The trade was a 12.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $2.86, for a total value of $33,653.62. Following the transaction, the chief financial officer owned 155,983 shares of the company’s stock, valued at $446,111.38. This represents a 7.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 83,779 shares of company stock valued at $353,387. 1.13% of the stock is currently owned by insiders.
Analyst Ratings Changes
Several research firms recently issued reports on XFOR. Weiss Ratings lowered X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $11.25.
Check Out Our Latest Analysis on X4 Pharmaceuticals
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.
X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.
Read More
- Five stocks we like better than X4 Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
